




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 231/38, A61K 31/415, C07D 401/04, 405/04, 409/04	A1	(11) International Publication Number: WO 97/40019 (43) International Publication Date: 30 October 1997 (30.10.97)
(21) International Application Number: PCT/GB97/01120 (22) International Filing Date: 23 April 1997 (23.04.97) (30) Priority Data: 9608435.5 24 April 1996 (24.04.96) GB (71) Applicant (for all designated States except US): CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVIS, Peter, David [GB/GB]; 10 Aston Park, Aston Rowant, Oxford OX9 5SW (GB). DAVIS, Jeremy, Martin [GB/GB]; 8 Suffolk Close, Wokingham, Berkshire RG41 1AU (GB). MOFFAT, David, Festus, Charles [GB/GB]; 14 Lonsdale Way, Holyport, Maidenhead, Berkshire SL6 2YX (GB). (74) Agents: HALLYBONE, Huw, George et al.; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: 5-AMINOPYRAZOLES USEFUL AS SELECTIVE INHIBITORS OF THE PROTEIN TYROSINE KINASE P56 ^{lck} (57) Abstract <p>Compounds of general formula (1) are described, wherein Ar is an optionally substituted aromatic or heteroaromatic group; X¹ is an oxygen or sulphur atom; R¹ is a hydrogen atom or a methyl group; R² is a hydrogen atom or a group -Alk¹ or -X²Alk¹ where Alk¹ is an optionally substituted aliphatic or heteroaliphatic group and X² is a -C(O)-, -C(S)-, or -S(O)_n group where n is an integer 1 or 2; R³ is a hydrogen atom or a group -Alk², [where Alk² is as defined for Alk¹], -X²Alk², -Ar¹ [where Ar¹ is an optionally substituted aromatic or heteroaromatic group], -Alk²Ar¹, or -X²Alk²Ar¹; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective inhibitors of the protein tyrosine kinase p56^{lck} and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate p56^{lck} activity is believed to have a role.</p> <div style="text-align: right; margin-top: 20px;">  <p style="text-align: right;">(1)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BEST AVAILABLE COPY

5-AMINOPYRAZOLES USEFUL AS SELECTIVE INHIBITORS OF THE PROTEIN TYROSINE KINASE P56^{lck}

This invention relates to a series of substituted pyrazoles, to processes for
5 their preparation, to pharmaceutical compositions containing them, and to
their use in medicine.


Protein kinases participate in the signalling events which control the
activation, growth and differentiation of cells in response to extracellular
10 mediators and to changes in the environment. In general, these kinases
fall into two groups; those which preferentially phosphorylate serine
and/or threonine residues and those which preferentially phosphorylate
tyrosine residues [Hanks, S K, Hunter T, FASEB. J. 9, 576-596 (1995)].
The serine/threonine kinases include for example, protein kinase C
15 isoforms [Newton A C, J. Biol. Chem. 270, 28495-28498 (1995)] and a
group of cyclin-dependent kinases such as cdc2 [Pines J, Trends in
Biochemical Sciences 18, 195-197 (1995)]. The tyrosine kinases include
membrane-spanning growth factor receptors such as the epidermal growth
factor receptor [Iwashita S and Kobayashi M. Cellular Signalling 4, 123-
20 132 (1992)], and cytosolic non-receptor kinases such as p56^{lck}, p59^{fyn},
ZAP-70 and csk kinases [Chan C *et al* Ann. Rev. Immunol. 12, 555-592
(1994)].

Inappropriately high protein kinase activity has been implicated in many
25 diseases resulting from abnormal cellular function. This might arise either
directly or indirectly, for example by failure of the proper control
mechanisms for the kinase, related for example to mutation,
overexpression or inappropriate activation of the enzyme; or by over- or
underproduction of cytokines or growth factors also participating in the
30 transduction of signal upstream or downstream of the kinase. In all of
these instances, selective inhibition of the action of the kinase might be
expected to have a beneficial effect.

We have now found a series of 5-aminopyrazole derivatives which are
35 potent and selective inhibitors of the protein tyrosine kinase p56^{lck}. The
compounds are of use in the prophylaxis and treatment of immune

diseases, hyperproliferative disorders and other diseases in which inappropriate p56^{lck} activity is believed to have a role.

- 5 Thus according to one aspect of the invention, we provide a compound of formula (1):



- 10 wherein

Ar is an optionally substituted aromatic or heteroaromatic group;

X¹ is an oxygen or sulphur atom;

R¹ is a hydrogen atom or a methyl group;

R² is a hydrogen atom or a group -Alk¹ or -X²Alk¹ where Alk¹ is an

- 15 optionally substituted aliphatic or heteroaliphatic group and X² is a -C(O)-, -C(S)-, or -S(O)_n group where n is an integer 1 or 2;

R³ is a hydrogen atom or a group -Alk², [where Alk² is as defined for Alk¹], -X²Alk², -Ar¹ [where Ar¹ is an optionally substituted aromatic or heteroaromatic group], -Alk²Ar¹, or -X²Alk²Ar¹;

- 20 and the salts, solvates, hydrates and N-oxides thereof.

Aromatic groups represented by the groups Ar or, when present, Ar¹ in compounds of formula (1) include for example mono- or bicyclic C₆₋₁₂ optionally substituted aromatic groups, for example optionally substituted
 25 phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl or indenyl groups.

Heteroaromatic groups represented by Ar or Ar¹ include for example C₁₋₉ optionally substituted heteroaromatic groups containing for example one,
 30 two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, the heteroaromatic groups may be for example

monocyclic or bicyclic heteroaromatic groups. Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaromatic groups include for example nine- to thirteen-membered heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.

Particular examples of heteroaromatic groups represented by Ar or Ar¹ include optionally substituted pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazole, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroisoquinolinyl, or imidyl, e.g. succinimidyl, phthalimidyl, or naphthalimidyl such as 1,8-naphthalimidyl.

Optional substituents which may be present on the aromatic or heteroaromatic groups represented by Ar or Ar¹ include one, two, three or more groups, each represented by the group R⁴. The substituent R⁴ may be selected from an atom or group R⁵ or -Alk³(R⁵)_m, where R⁵ is a halogen atom, or an amino (-NH₂), substituted amino, nitro, cyano, hydroxyl (-OH), substituted hydroxyl, formyl, carboxyl (-CO₂H), esterified carboxyl, thiol (-SH), substituted thiol, -COR⁶ [where R⁶ is an -Alk³(R⁵)_m, aryl or heteroaryl group], -CSR⁶, -SO₃H, -SO₂R⁶, -SO₂NH₂, -SO₂NHR⁶, SO₂N[R⁶]₂, -CONH₂, -CSNH₂, -CONHR⁶, -CSNHR⁶, -CON[R⁶]₂, -CSN[R⁶]₂, -NHSO₂H, -NHSO₂R⁶, -N[SO₂R⁶]₂, -NHSO₂NH₂, -NHSO₂NHR⁶, -NHSO₂N[R⁶]₂, -NHCOR⁶, -NHCSR⁶, -NHC(O)OR⁶, aryl or heteroaryl group; Alk³ is a straight or branched C₁₋₆alkylene, C₂₋₆alkenylene or C₂₋₆alkynylene chain, optionally interrupted by one, two or three -O- or -S- atoms or -S(O)_n or -N(R⁷)- groups [where R⁷ is a

hydrogen atom or C₁₋₆alkyl, e.g. methyl or ethyl group]; and m is zero or an integer 1, 2 or 3.

5 When in the group -Alk³(R⁵)_m m is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R⁵ may be present on any suitable carbon atom in -Alk³. Where more than one R⁵ substituent is present these may be the same or different and may be present on the same or different atom in -Alk³. Clearly, when m is zero and no substituent R⁵ is present the alkylene, alkenylene or alkynylene chain
10 represented by Alk³ becomes an alkyl, alkenyl or alkynyl group.

When R⁵ is a substituted amino group it may be for example a group -NHR⁶ [where R⁶ is as defined above] or a group -N[R⁶]₂ wherein each R⁶ group is the same or different.

15

When R⁵ is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.

20 When R⁵ is a substituted hydroxyl or substituted thiol group it may be for example a group -OR⁶ or a -SR⁶ or -SC(NH₂⁺)NH₂ group respectively.

Esterified carboxyl groups represented by the group R⁵ include groups of formula -CO₂Alk⁴ wherein Alk⁴ is a straight or branched, optionally substituted C₁₋₈alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-
25 butyl, i-butyl, s-butyl or t-butyl group; a C₆₋₁₂arylC₁₋₈alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C₆₋₁₂aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C₆₋₁₂aryloxyC₁₋₈alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl,
30 1-naphthyl-oxymethyl, or 2-naphthyloxymethyl group; an optionally substituted C₁₋₈alkanoyloxyC₁₋₈alkyl group, such as a pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a C₆₋₁₂aroxyloxyC₁₋₈alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk⁴ group
35 include R⁵ substituents described above.

When Alk³ is present in or as a substituent R⁴ it may be for example a methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylene chain, optionally interrupted by one, two, or three -O- or -S-, atoms or
 5 -S(O)-, -S(O)₂- or -N(R⁷)- groups.

Aryl or heteroaryl groups represented by the groups R⁵ or R⁶ include mono- or bicyclic optionally substituted C₆₋₁₂ aromatic or C₁₋₉
 10 heteroaromatic groups as described above for the groups Ar and Ar¹. The aromatic and heteroaromatic groups may be attached to the remainder of the compound of formula (1) by any carbon or hetero e.g. nitrogen atom as appropriate.

15 Particularly useful atoms or groups represented by R⁴ include fluorine, chlorine, bromine or iodine atoms, or C₁₋₆alkyl, e.g. methyl or ethyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, C₁₋₆hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, C₁₋₆alkylthiol e.g. methylthiol or ethylthiol, C₁₋₆alkoxy, e.g. methoxy or ethoxy, C₅₋₇cycloalkoxy, e.g. cyclopentyloxy,
 20 haloC₁₋₆alkyl, e.g. trifluoromethyl, haloC₁₋₆alkoxy, e.g. trifluoromethoxy, C₁₋₆alkylamino, e.g. methylamino or ethylamino, amino (-NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, imido, such as phthalimido or naphthalimido, e.g. 1,8-naphthalimido, 1,1,3-trioxobenzo-[d]thiazolidino, nitro, cyano, hydroxyl
 25 (-OH), formyl [HC(O)-], carboxyl (-CO₂H), -CO₂Alk⁴ [where Alk⁴ is as defined above], C₁₋₆alkanoyl e.g. acetyl, thiol (-SH), thioC₁₋₆alkyl, e.g. thiomethyl or thioethyl, -SC(NH₂+)NH₂, sulphonyl (-SO₃H), C₁₋₆alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (-SO₂NH₂), C₁₋₆alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆
 30 dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylamino-sulphonyl, carboxamido (-CONH₂), optionally substituted C₁₋₆alkylaminocarbonyl, e.g. methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, 2-aminoethylaminocarbonyl, aminopropylaminocarbonyl, N-(methoxycarbonyl)-2-amino-carbonyl, N-(methoxycarbonyl)-3-aminopropylaminocarbonyl, N-(butoxycarbonyl)-3-aminopropylaminocarbonyl, C₁₋₆ dialkylaminocarbonyl, e.g. dimethylamino-

carbonyl or diethylaminocarbonyl, sulphonylamino (-NHSO₂H), C₁₋₆alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, optionally substituted phenylsulphonylamino, e.g. 2-, 3- or 4-substituted phenylsulphonylamino such as 2-nitrophenylsulphonylamino, aminosulphonylamino (-NHSO₂NH₂), C₁₋₆alkylamino-sulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C₁₋₆dialkylaminosulphonylamino, e.g. dimethylamino-sulphonylamino or diethylaminosulphonylamino, phenylaminosulphonylamino, C₁₋₆alkanoylamino, e.g. acetylamino, C₁₋₆alkanoylaminoC₁₋₆alkyl, e.g. acetylaminomethyl, or C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino groups.

Where desired, two R⁴ substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₂₋₆alkylenedioxy group such as ethylenedioxy.

It will be appreciated that where two or more R⁴ substituents are present, these need not necessarily be the same atoms and/or groups.

20

When the group -Alk¹ or -Alk² is present in the compounds of formula (1) it may be for example an optionally substituted C₁₋₁₀aliphatic or C₁₋₁₀heteroaliphatic group.

Particular examples of aliphatic groups represented by -Alk¹ or -Alk² include optionally substituted straight or branched C₁₋₆alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl groups. Particular heteroaliphatic groups include the aliphatic groups just recited but each additionally containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.

30

Thus, for example, -Alk¹ or -Alk² when present in compounds of formula (1) may be an optionally substituted -CH₃, -CH₂CH₃, -(CH₂)₂CH₃, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃, -(CH₂)₄CH₃, -(CH₂)₅CH₃, -CHCH₂, -CHCHCH₃, -CH₂CHCH₂, -CHCHCH₂CH₃, -CH₂CHCHCH₃, -(CH₂)₂CHCH₂, -CHCH(CH₂)₂CH₃, -CH₂CHCHCH₂CH₂, -(CH₂)₂CHCHCH₃, -(CH₂)₃CHCH₂,

35

-CHCH(CH₂)₃CH₃, -CH₂CHCH(CH₂)₂CH₃, -(CH₂)₂CHCHCH₂CH₃,
 -(CH₂)₃CHCHCH₃, or -(CH₂)₄CH₂CH₂ group, each of said groups, where
 appropriate, being optionally interrupted by one or two -O- or -S- atoms
 and/or -C(O)-, -C(S)-, -S(O)-, -S(O)₂-, -N(R⁷)-, -CON(R⁷)-, -OC(O)N(R⁷)-,
 5 -CSN(R⁷)-, -N(R⁷)CO, -N(R⁷)C(O)O-, -N(R⁷)CS-, -SON(R⁷)-, -SO₂N(R⁷)-,
 -N(R⁷)SO₂-, -N(R⁷)CON(R⁷)-, -N(R⁷)CSN(R⁷)-, -N(R⁷)SON(R⁷)- or
 -N(R⁷)SO₂N(R⁷)- groups.

Optional substituents which may be present on -Alk¹ or -Alk² in
 10 compounds of formula (1) include one, two, three or more R⁸ substituents,
 where R⁸ is as defined above for the substituent R⁴.

The presence of certain substituents in the compounds of formula (1) may
 enable salts of the compounds to be formed. Suitable salts include
 15 pharmaceutically acceptable salts, for example acid addition salts derived
 from inorganic or organic acids, and salts derived from inorganic and
 organic bases.

Acid addition salts include hydrochlorides, hydrobromides, hydroiodides,
 20 alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or
 isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or
 napsylates, phosphates, sulphates, hydrogen sulphates, acetates,
 trifluoroacetates, propionates, citrates, maleates, fumarates, malonates,
 succinates, lactates, oxalates, tartrates and benzoates.

25 Salts derived from inorganic or organic bases include alkali metal salts
 such as sodium or potassium salts, alkaline earth metal salts such as
 magnesium or calcium salts, and organic amine salts such as morpholine,
 piperidine, dimethylamine or diethylamine salts.

30 Particularly useful salts of compounds according to the invention include
 pharmaceutically acceptable salts, especially acid addition
 pharmaceutically acceptable salts.

35 It will be appreciated that depending on the nature of the substituents R¹,
 R², R³, R⁴ and R⁵ the compounds of formula (1) may exist as geometrical

isomers and/or may have one or more chiral centres so that enantiomers or diastereomers may exist. It is to be understood that the invention extends to all such isomers of the compounds of formula (1), and to mixtures thereof, including racemates.

5

In general in compounds of formula (1) the group R^1 is preferably a hydrogen atom.

X^1 in compounds of formula (1) is preferably an oxygen atom.

10

In another general preference, the group R^2 in compounds of formula (1) is preferably a hydrogen atom.

One particularly useful group of compounds according to the invention is that wherein Ar is an optionally substituted aromatic group, especially an optionally substituted phenyl or naphthyl group. In compounds of this type Ar may be in particular a phenyl group or a phenyl group substituted by one, two, three or more R^4 groups as defined herein. Especially useful Ar groups include phenyl or monosubstituted phenyl groups where the
15
20
substituent is a R^4 group as defined herein. Particularly useful R^4 substituents in groups of this type include halogen atoms and optionally substituted C_{1-6} alkyl groups, especially a chlorine atom or a methyl group.

In a further preference, the group R^3 in compounds of formula (1) is an
25
-Alk², -X³Alk², -Ar¹, -Alk²Ar, or -X³Alk²Ar¹ group. Particularly useful compounds of this type are those wherein R^3 is an -Alk² or Ar¹ group. Especially useful R^3 groups include optionally substituted C_{1-6} alkyl, optionally substituted phenyl or optionally substituted pyridyl groups. Particular groups of this type include t-butyl, phenyl or 2-pyridyl groups,
30
each of said phenyl or pyridyl groups being optionally substituted by a group R^4 . Particularly useful R^4 groups include halogen atoms or amino (-NH₂), nitro, methyl, ethyl, methoxy or ethoxy groups.

Compounds according to the invention are potent and selective inhibitors
35
of the protein tyrosine kinase p56^{lck}. In particular, compounds of the invention inhibit the p56^{lck} enzyme at concentrations at which they have

little or no useful inhibitory action on other protein kinases, in particular ZAP-70, protein kinase C and Csk kinases. The ability of the compounds to act in this way may be simply determined by the tests described in the Examples hereinafter.

5

The compounds according to the invention are thus of particular use in the prophylaxis and treatment of diseases or disorders in mammals, especially humans, in which inappropriate protein tyrosine kinase action plays a role, and the invention extends to such a use. Particular examples of diseases and disorders in which inappropriate tyrosine kinase action plays a role include autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus, in transplant rejection, in graft v host disease, in hyperproliferative disorders such as tumours and psoriasis, and in diseases in which cells receive pro-inflammatory signals such as asthma, inflammatory bowel disease and pancreatitis.

For use as just described the compounds according to the invention may be administered as pharmaceutical compositions containing an amount of the compound effective in the prophylaxis or treatment of the disease or disorder. Thus according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.

Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets

may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations
5 may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

- 10 Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

15

The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule or multi dose containers, e.g. glass vials. The compositions for injection
20 may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

25

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.

30

For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichloro-
35 fluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

5

The therapeutically effective amount of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around
10 100ng/kg to 100mg/kg e.g. around 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.


15

The compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process description, the symbols Ar, X¹, R¹, R², and R³, when used in the formulae depicted are to be
20 understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions.
25 Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis", John Wiley and Sons, 1981]. In some instances, deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described hereinafter are to be
30 understood to extend to such removal of protecting groups.

Thus according to a further aspect of the invention, a compound of formula (1) wherein R¹ and R² is each a hydrogen atom may be prepared by reaction of an alkene of formula (2):

35

12



[wherein L¹ is an electron-donating leaving group], with a hydrazine R³NHNH₂ or a salt thereof.

5

Particular examples of groups represented by L¹ include -OR, -OSO₂R, -SR and -N(R)₂ groups [where R is an aliphatic or heteroaliphatic group, as described herein for the group Alk¹ and may be for example an optionally substituted C₁₋₆alkyl group, such as a methyl or trifluoromethyl group].

10

The reaction may be performed in the presence of an organic solvent, for example an alcohol such as methanol or ethanol, or an ether, e.g. a cyclic ether such as tetrahydrofuran at an elevated temperature e.g. the reflux temperature, optionally in the presence of a base, e.g. an inorganic base such as an alkali metal base, e.g. sodium hydroxide or sodium carbonate.


15

Alkenes of formula (2) and hydrazines of formula R³NHNH₂ are either known, [see for example Tominaga, Y, *et al*, J. Het. Chem., 27, 647-660, (1990)] and in some instances commercially available compounds, or may be obtained from known starting materials by methods analogous to those used for the preparation of the known compounds.

20

In another process according to the invention, a compound of formula (1) wherein X¹ is an oxygen atom and R¹ is a hydrogen atom may be prepared by heating a nitrile of formula (3):

25




optionally either in the presence of a base, for example an inorganic base such as an alkali metal base, e.g. sodium hydroxide, in a solvent, for example an alcohol such as ethanol, or in the presence of a catalyst, for example a complex metal catalyst such as a palladium or ruthenium catalyst, e.g. tetrakis(triphenylphosphine)ruthenium dihydride in an inert organic solvent such as an ether, e.g. dimethoxyethane or dioxane or an aromatic hydrocarbon such as toluene or benzene.

The reaction may be performed at any suitable elevated temperature up to and above the reflux temperature depending on the nature of the reactants and solvents used.

Nitriles of formula (3) wherein R² is a hydrogen atom may be prepared by reaction of a dinitrile of formula (4):

15



[where L¹ is as described above]
with a hydrazine R³NHNH₂ or a salt thereof using the reagents and conditions described above for the preparation of compounds of formula (1) from alkenes of formula (2).

Intermediate dinitriles of formula (4) are either known compounds [see for example Tominaga, Y *et al* *ibid*; and Shioiri, T & Hamada, Y, J. Org. Chem. **43**, 3631 (1978)] or may be prepared from known starting materials by methods analogous to those used for the preparation of the known compounds, for example as described in the Examples hereinafter. Thus, for example, in one general process malononitrile may be reacted with an appropriate acid ArCO₂H or activated derivative thereof followed where necessary by generation of the leaving group L¹, for example by treating any ArCOCH(CN)₂ compound so obtained with trifluoromethanesulphonic anhydride in the presence of a base such as collidine to obtain the desired dinitrile ArC(L¹)C(CN)₂ where L¹ is a leaving group -OSO₂CF₃.

Where it is desired to obtain an intermediate of formula (3) wherein R^2 is other than a hydrogen atom this may be obtained by interconversion of the corresponding compound of formula (3) wherein R^2 is a hydrogen atom, by alkylation or acylation, as described hereinafter for the interconversion of compounds of formula (1).

Compounds of formula (1) may also be prepared by interconversion of other compounds of formula (1) and it is to be understood that the invention extends to such interconversion processes. Thus, for example, standard substitution approaches employing for example alkylation, arylation, acylation, thioacylation, sulphonylation, formylation or coupling reactions may be used to add new substituents to and/or extend existing substituents in compounds of formula (1). Alternatively existing substituents in compounds of formula (1) may be modified by for example oxidation, reduction or cleavage reactions to yield other compounds of formula (1).

The following describes in general terms a number of approaches which can be employed to modify existing Ar, R^1 , R^2 , and R^3 groups in compounds of formula (1). It will be appreciated that each of these reactions will only be possible where one or more appropriate functional groups exist in the compound of formula (1).

Thus, for example alkylation or arylation of a compound of formula (1), for example to introduce a group Alk^1 or Ar^1 may be achieved by reaction of the compound with a reagent Alk^1L^2 or Ar^1L^2 , where L^2 is a leaving group. This reaction is particularly suitable for alkylation or arylation of compounds of formula (1) where R^2 is a hydrogen atom.

Leaving groups represented by L^2 include halogen atoms such as iodine, chlorine or bromine atoms or sulphonyloxy groups such as alkyl- or arylsulphonyloxy groups, e.g. methylsulphonyloxy or p-toluenesulphonyloxy.

The alkylation or arylation reaction may be carried out in the presence of a base, e.g. an inorganic base such as a carbonate, e.g. caesium or

potassium carbonate, an alkoxide, e.g. potassium t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran, at around 0°C to around 40°C.

5

Alkylation as just described may also be used at low temperature in the preparation of a compound of formula (1) wherein R¹ is a methyl group from the corresponding compound of formula (1) in which R¹ is a hydrogen atom.

10

In another general example of an interconversion process, a compound of formula (1) may be acylated or thioacylated, for example to introduce a group -C(O)Alk¹ or -C(S)Alk¹. The reaction may be performed for example with an acyl or thioacyl halide or anhydride in the presence of a base, such as a tertiary amine e.g. triethylamine in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at for example ambient temperature, or by reaction with a thioester in an inert solvent such as tetrahydrofuran at a low temperature such as around 0°C. The reaction is particularly suitable for use with compounds of formula (1) where R² is a hydrogen atom.

15

20

Compounds of formula (1) may be prepared in another general interconversion reaction by sulphonylation, for example by reaction of the compound with a reagent R⁶S(O)_nL² where L² is a leaving group as described above in the presence of a base, for example an inorganic base such as sodium hydride in a solvent such as an amide, e.g. a substituted amide such as dimethylformamide at for example ambient temperature. The reaction may in particular be performed with compounds of formula (1) in which Ar and/or Ar¹ possesses a primary or secondary amino group.

25

30

In further examples of interconversion reactions according to the invention compounds of formula (1) may be prepared from other compounds of formula (1) by modification of existing functional groups in the latter.

35

Thus in one example, ester groups -CO₂Alk⁴ in compounds of formula (1) may be converted to the corresponding acid [-CO₂H] by acid- or base-

catalysed hydrolysis depending on the nature of the group Alk⁴. Acid- or base-catalysed hydrolysis may be achieved for example by treatment with an organic or inorganic acid, e.g. trifluoroacetic acid in an aqueous solvent or a mineral acid such as hydrochloric acid in a solvent such as dioxan or
5 an alkali metal hydroxide, e.g. lithium hydroxide in an aqueous alcohol, e.g. aqueous methanol.

In a second example, -OR⁶ [where Alk represents an alkyl group such as methyl group] groups in compounds of formula (1) may be cleaved to the
10 corresponding alcohol -OH by reaction with boron tribromide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at a low temperature, e.g. around -78°C.

In another example, alcohol -OH groups in compounds of formula (1) may
15 be converted to a corresponding -OR⁶ group by coupling with a reagent R⁶OH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl-, diisopropyl-, or dimethylazodicarboxylate.

20 Aminosulphonylamino [-NHSO₂NH₂] groups in compounds of formula (1) may be obtained, in another example, by reaction of a corresponding amine [-NH₂] with sulphamide in the presence of an organic base such as pyridine at an elevated temperature, e.g. the reflux temperature.

25 In a further example, amine [-NH₂] groups in compounds of formula (1) may be obtained by hydrolysis from a corresponding imide by reaction with hydrazine in a solvent such as an alcohol, e.g. ethanol at ambient temperature.

30 In another example, a nitro [-NO₂] group may be reduced to an amine [-NH₂], for example by catalytic hydrogenation using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon in a solvent such as an ether, e.g. tetrahydrofuran or an alcohol e.g. methanol, or by chemical reduction using for example a metal,
35 e.g. tin or iron, in the presence of an acid such as hydrochloric acid.

In a further example, amide [-CONHR⁶] groups in compounds of formula (1) may be obtained by coupling a corresponding acid [-CO₂H] or an active derivative thereof, e.g. an acid anhydride, imide or halide, with an amine R⁶NH₂. The coupling reaction may be performed using standard conditions for reactions of this type. Thus for example the reaction may be carried out in a solvent, for example an inert organic solvent such as an amide, e.g. a substituted amide such as dimethylformamide, at a low temperature, e.g. -30°C to ambient temperature, optionally in the presence of a base, e.g. an organic base such as a cyclic amine, e.g. N-methylmorpholine, and where necessary in the presence of a condensing agent, for example a diimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.

N-oxides of compounds of formula (1) may be prepared for example by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70°C to 80°C, or alternatively by reaction with a peracid such as peracetic acid in a solvent, e.g. dichloromethane, at ambient temperature.

20

The following Examples illustrate the invention.

All temperatures are in °C. The following abbreviations are used:

THF - tetrahydrofuran; DMF - dimethylformamide;

25 DMSO - dimethylsulphoxide

EXAMPLE 1

5-Amino-1-tert-butyl-3-(4'-chlorophenyl)pyrazole-4-carboxamide

To a solution of tert-butyl hydrazine hydrochloride (523 mg, 3.50 mmol) in ethyl alcohol (20 ml) was added powdered sodium hydroxide (168 mg, 4.20 mmol), followed by 3-(4-chlorophenyl)-2-cyano-3-methylthioacrylamide (884 mg, 3.50 mmol) and the mixture was heated at reflux for 4h. On cooling, the solvent was removed under reduced pressure and the residue partitioned between water (80 ml) and ethyl acetate (80 ml). The aqueous layer was further extracted with ethyl acetate (2 x 80 ml) and the combined organic layers were washed with brine (1 x 100 ml), dried

(MgSO₄) and concentrated under reduced pressure. The residue was subjected to column chromatography (SiO₂, 45-75% ethyl acetate-hexane) to afford the title compound (780 mg) after recrystallisation from methanol as a colourless solid m.p. 156°. δ_H (d⁶ DMSO) 1.66 (9H, s), 5.16 (2H, br s), 5.68 (2H, br s), 7.42 (2H, dt, Δ 8.6, 2.1Hz), and 7.51 (2H, dt, Δ 8.7, 2.1Hz).

The acrylamide starting material was prepared according to the method of Y Tominaga *et al*, J. Het. Chem (1990), 27, 647-660 [see for example page 653 describing the preparation of compound 8h].

10

The following compound was prepared in a similar manner:

EXAMPLE 2

5-Amino-3-(4'-chlorophenyl)-1H-pyrazole-4-carboxamide

15 From 3-(4-chlorophenyl)-2-cyano-3-methylthioacrylamide (290 mg, 1 mmol) and hydrazine monohydrate (60 mg, 1.2 mmol) to give the title compound (60 mg) after recrystallisation from ethyl acetate as a colourless solid, m.p. 224°. δ_H (d⁶ DMSO) Minor Tautomer 5.18 (2H br s), 6.25 (2H, br s), 7.52 (4H, m), 12.18 (1H, br s), Major Tautomer 5.95 (2H, br s), 6.25
20 (2H, br s), 7.52 (4H, m), and 11.92 (1H, br s).

EXAMPLE 3

5-Amino-1-tert-butyl-3-(4'-trifluoromethylphenyl)pyrazole-4-carboxamide

25 To a solution of 5-amino-1-tert-butyl-4-cyano-3-(4'-trifluoromethylphenyl)-pyrazole (308 mg, 1.0 mmol) in ethanol (15 ml) was added 10M sodium hydroxide (3 ml) and the mixture heated at reflux for 72h. On cooling, ethanol was removed under reduced pressure and water (50 ml) added. The resulting precipitate was collected by filtration, and washed with water
30 (2 x 25 ml), to give the title compound (200 mg) as a colourless solid after recrystallisation from ethyl acetate m.p. 210-211°. δ_H (CDCl₃) 1.67 (9H, s), 5.16 (2H, br s), 5.69 (2H, br s), and 7.71 (4H, s).

The pyrazole starting material for this reaction was prepared as follows:

5-Amino-1-tert-butyl-4-cyano-3-(4'-trifluoromethylphenyl)pyrazole

35 To a solution of 2-(4-trifluoromethylbenzoyl)propanedinitrile (1.70 g, 7.15 mmol) in CH₂Cl₂ (60 ml), was added collidine (1.89 ml, 14.3 mmol)

followed by trifluoromethanesulphonic anhydride (1.45 ml, 8.58 mmol) and the mixture stirred at room temperature for 2h. The reaction was concentrated under reduced pressure and the residue dissolved in THF (100 ml). This was added to a suspension of tert-butyl hydrazine hydrochloride (0.98 g, 7.86 mmol) and sodium carbonate (1.14 g, 10.73 mmol) in THF and heated at reflux for 2.5h. The reaction was again concentrated under reduced pressure, the residue dissolved in ethyl acetate (100ml), washed with 2M hydrochloric acid (1 x 100 ml), water (1 x 100 ml) and brine (1 x 100 ml), dried (MgSO₄) and solvent then removed under reduced pressure. The resulting solid was subjected to column chromatography to give the title compound (700 mg) as a pale pink solid after recrystallisation from ether, m.p. 155-156°. δ_{H} (CDCl₃) 1.68 (9H, s), 4.46 (2H, br s), 7.66 (2H, d, J 8.0Hz), and 8.03 (2H, d, J 8.0Hz). The dinitrile starting material for this reaction was prepared as follows:

2-(4-Trifluoromethylbenzoyl)propanedinitrile

To a solution of α , α' , α'' -trifluoro-p-toluic acid (4.56 g, 24.0 mmol) and malononitrile (1.45 g, 21.8 mmol) in DMF (50 ml) at 0° was added diethylcyanophosphonate (3.65 ml, 24.0 mmol) followed by triethylamine (9.40 ml, 69.8 mmol) and the mixture was stirred at 25° for 16h. The reaction was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (150 ml) and washed with 2 M hydrochloric acid (2 x 100 ml) and then with saturated NaHCO₃ (3 x 150 ml). The basic layers were acidified to pH 1 with 6M hydrochloric acid and extracted with ethyl acetate (3 x 125 ml). The combined organic layers were dried (MgSO₄) and concentrated under reduced pressure to give the title compound (1.90 g) as an orange solid which was not purified. δ_{H} (CDCl₃) 7.73 (4H, s), and 10.70 (1H, br s).

The following title compounds and intermediates of Examples 4-8 were prepared in a similar manner to the title compound and intermediates of Example 3.

EXAMPLE 4

5-Amino-1-tert-butyl-3-(3-furyl)pyrazole-4-carboxamide

From 5-amino-1-tert-butyl-4-cyano-3-(3-furyl)pyrazole (500 mg, 2.17 mmol) to give the title compound (340 mg) as a colourless solid m.p. 177°.

δ_H (CDCl₃) 1.65 (9H, s), 5.48 (2H, br s), 5.66 (2H, br s), 6.62 (1H, dd, \downarrow 1.8, 0.8Hz), 7.51 (1H, t, \downarrow 1.6Hz), and 7.68 (1H, dd, \downarrow 1.6, 0.9Hz).

The pyrazole starting material was obtained from 2-(3-furoyl)propanedinitrile as an orange solid m.p. 98-99°. δ_H (CDCl₃) 1.69 (9H, s), 6.83 (1H, dd, \downarrow 1.7, 0.8Hz), 7.44 (1H, t, \downarrow 1.7Hz) and 7.98 (1H, m). The 2-(3-furoyl)propanedinitrile was obtained from 3-furoic acid as an off-white solid. δ_H (d⁶ DMSO) 6.77 (1H, dd, \downarrow 1.8, 0.8Hz), 7.70 (1H, t, \downarrow 1.7Hz), 8.14 (1H, dd, \downarrow 1.5, 0.8Hz), and 8.89 (1H, br s).

10 **EXAMPLE 5**

5-Amino-1-tert-butyl-3-(3-thienyl)pyrazole-4-carboxamide

From 5-amino-1-tert-butyl-4-cyano-3-(3-thienyl)pyrazole (492 mg, 2.0 mmol) to give the title compound (60 mg), as a colourless solid. m.p. 173-174°. δ_H (CDCl₃) 1.71 (9H, s), 4.51 (2H, br s), 5.78 (2H, br s), 7.29 (1H, dd, \downarrow 4.9, 1.2Hz), 7.47 (1H, dd, \downarrow 4.9, 3.0Hz) and 7.60 (1H, m).

The pyrazole starting material was obtained from 2-(3-thienoyl)propanedinitrile as an off-white solid m.p. 132-133°. δ_H (CDCl₃) 1.67 (9H, s), 4.35 (2H, br s), 7.34 (1H, dd, \downarrow 5.0, 3.0Hz), 7.59 (1H, dd, \downarrow 5.0, 1.2Hz), and 7.84 (1H, dd, \downarrow 3.0, 1.3Hz). The 2-(3-thienoyl)propanedinitrile was obtained from 3-thiophenecarboxylic acid as a yellow solid m.p. 142-145°. δ_H (d⁶ DMSO) 6.86 (1H, br s), 7.38 (1H, dd, \downarrow 5.1, 1.3 Hz), 7.52 (1H, dd, \downarrow 5.1, 2.9Hz) and 7.99 (1H, dd, \downarrow 3.0, 1.3Hz).

EXAMPLE 6

25 **5-Amino-1-tert-butyl-3-(4-tolyl)pyrazole-4-carboxamide**

From 5-amino-1-tert-butyl-4-cyano-3-(4-tolyl)pyrazole (460 mg, 1.81 mmol) to give the title compound (128 mg) as a colourless solid, m.p. 240-242°. δ_H (d⁶ DMSO) 1.55 (9H, s), 2.34 (3H, s), 6.26 (2H, s), 7.24 (2H, d, \downarrow 8.0Hz), and 7.33 (2H, d, \downarrow 8.0Hz).

30 The pyrazole starting material was obtained from 2-(4-toluoyl)propanedinitrile as a yellow solid m.p. 163°. δ_H (CDCl₃) 1.67 (9H, s), 2.36 (3H, s), 4.30 (2H, br s), 7.20 (2H, d, \downarrow 8.2Hz) and 7.80 (2H, d, \downarrow 8.2Hz). The 2-(4-toluoyl)propanedinitrile was obtained from p-toluic acid as an off-white solid m.p. >190° (decomp.). δ_H (d⁶ DMSO) 2.35 (3H, s),
35 7.27 (2H, d, \downarrow 8.0Hz), 7.52 (2H, d, \downarrow 8.0Hz), and 10.82 (1H, br s).

EXAMPLE 7**5-Amino-1-tert-butyl-3-(3,4,5-trimethoxyphenyl)pyrazole-4-carboxamide**

From 5-amino-1-tert-butyl-4-cyano-3-(3,4,5-trimethoxyphenyl)pyrazole (443 mg, 1.34 mmol) to give the title compound (30 mg) as a colourless solid m.p. 180-192°. δ_{H} (d^6 DMSO) 1.55 (9H, s), 3.69 (3H, s), 3.78 (6H, s), 6.29 (2H, br s), and 6.71 (2H, s).

The pyrazole starting material was obtained from 2-(3,4,5-trimethoxybenzoyl)propanedinitrile as an off-white solid m.p. 158-160°. δ_{H} (CD_3OD) 1.64 (9H, s), 3.79 (3H, s), 3.87 (6H, s), 4.80 (2H, s) and 7.14 (2H, s). The 2-(3,4,5-trimethoxybenzoyl)propanedinitrile was obtained from 3,4,5-trimethoxybenzoic acid as an off-white solid m.p. >140° (decomp). δ_{H} (d^6 DMSO) 3.69 (3H, s), 3.75 (6H, s), 3.95 (1H, br s), and 6.99 (2H, s).

EXAMPLE 8

From 5-amino-1-tert-butyl-4-cyano-3-(2-naphthyl)pyrazole (220 mg, 0.8 mmol) to give the title compound (44 mg) as a colourless solid m.p. 224-225°C. δ_{H} (CDCl_3) 1.69 (9H, s), 5.22 (2H, br s), 5.71 (2H, br s), 7.50-7.54 (2H, m), 7.65 (1H, dd, J 8.4, 1.6Hz), 7.80-7.93 (3H, m), and 8.04 (1H, s).

The pyrazole starting material was obtained from 2-(2-naphthoyl)propanedinitrile as a colourless solid m.p. 121°. δ_{H} (CDCl_3) 1.71 (9H, s), 4.38 (2H, br s), 7.45-7.51 (2H, m), 7.81-7.93 (3H, m), 8.05 (1H, dd, J 8.6, 1.8Hz), and 8.41 (1H, s). The 2-(2-naphthoyl)propanedinitrile was obtained from 2-naphthoic acid as a yellow solid m.p. 195° (decomp.). δ_{H} (CDCl_3) 7.57-7.66 (2H, m), 7.71 (1H, dd, J 8.3, 1.7Hz), 7.89 (1H, d, J 7.6Hz), 7.94 (2H, d, J 8.3Hz), and 8.26 (1H, s).

EXAMPLE 9**5-Amino-1-phenyl-3-(4-tolyl)pyrazole-4-carboxamide**

From 5-amino-4-cyano-1-phenyl-3-(4-tolyl)pyrazole (185 mg, 0.68 mmol) in a similar manner to the compound of Example 3 to give the title compound (29 mg) as a colourless solid m.p. 186-187° δ_{H} (CDCl_3) 2.41 (3H, s), 5.33 (2H, br s), 5.74 (2H, br s), 7.28 (2H, d, J 8.1Hz), 7.36-7.41 (1H, m), 7.48-7.53 (3H, m), 7.54 (1H, m), and 7.61 (2H, d, J 8.6Hz).

The pyrazole starting material for the above process was prepared as a colourless solid m.p. 169-170° δ_{H} (CDCl_3) 2.39 (3H, s), 4.64 (2H, br s), 7.16-7.32 (3H, m), 7.41-7.59 (4H, m), and 7.87 (2H, d, J 8.2Hz) from

phenylhydrazine and 2-(4-toluoyl)propanedinitrile in a similar manner to the intermediate pyrazole of Example 3.

EXAMPLE 10

5-Amino-1-tert-butyl-3-(4-methoxycarbonylphenyl)pyrazole-4-carboxamide

A mixture of 5-amino-1-tert-butyl-4-cyano-3-(4-methoxycarbonylphenyl)-pyrazole (448 mg, 1.5 mmol) and tetrakis(triphenylphosphine)ruthenium dihydride in dimethoxyethane (1 ml) and water (54 μ l) was heated at 120°
under a nitrogen atmosphere in a sealed tube for 18h. The reaction was concentrated under reduced pressure and the residue subjected to column chromatography (silica 4% methanol-CH₂Cl₂) to give the title compound (170 mg) after recrystallisation from ethyl acetate as a colourless solid m.p. 237-239°. δ_H (CDCl₃) 1.67 (9H, s), 4.39 (3H, s), 5.10 (2H, br s), 5.69 (2H, br s), 7.66 (2H, d, \downarrow 8.2Hz), and 8.11 (2H, d, \downarrow 8.3Hz).
The pyrazole starting material used in the above process was prepared as a light yellow solid m.p. 202-203°. δ_H (CDCl₃) 1.69 (9H, s), 3.93 (3H, s), 4.39 (2H, br s), 8.00 (2H, dt, \downarrow 7.6, 1.4Hz), and 8.08 (2H, dt, \downarrow 8.8, 2.0Hz) from 2-(4-methoxycarbonylbenzoyl)propanedinitrile in a similar
manner to the intermediate pyrazole of Example 3.
The 2-(4-methoxycarbonylbenzoyl)propanedinitrile was obtained from monomethylterephthalate as an orange solid m.p. 153-160° (decomp.). δ_H (d⁶ DMSO) 3.85 (3H, s), 6.62 (1H, br s), 7.65 (2H, dt, \downarrow 8.6, 1.9Hz), and 7.93 (2H, dt, \downarrow 8.6, 2.0Hz).

EXAMPLE 11

5-Amino-1-tert-butyl-3-phenylpyrazole-4-carboxamide

From 5-amino-1-tert-butyl-4-cyano-3-phenylpyrazole (720mg, 3.0mmol) in a similar manner to the compound of Example 3 to give the title compound as white crystals (92mg) m.p. 177-178°. δ_H (CDCl₃) 7.54 (2H, m), 7.45 (3H, m), 5.69 (2H, br s), 5.21 (2H, br s) and 1.67 (9H, s).
The pyrazole starting material for the above process was obtained as described for the intermediate pyrazole of Example 3 from 2-benzoylpropanedinitrile as a white crystalline solid m.p. 124-125°. δ_H (CDCl₃) 7.93 (2H, m), 7.42 (3H, m) 4.37 (2H, br s) and 1.68 (9H, s). The 2-benzoylpropanedinitrile was prepared from benzoic acid following the

procedure described in Example 3 as a light yellow solid. δ H (CDCl₃) 7.81 (2H, d, $\underline{\text{J}}$ 7.1Hz), 7.66 (1H, t, $\underline{\text{J}}$ 7.1Hz), 7.54 (2H, apparent t, $\underline{\text{J}}$ 7.1Hz) and 6.10 (1H, br s).

5 **EXAMPLE 12**

5-Amino-3-(4-tolyl)-1-(3-trifluoromethoxyphenyl)pyrazole-4-carboxamide

Powdered sodium hydroxide (88mg, 2.2mmol) was added to a solution of 3-trifluoromethoxyphenyl hydrazine hydrochloride (503mg, 2.2mmol) and
10 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (464mg, 2.0mmol) in ethanol (20ml) and the mixture heated at reflux for 18h. On cooling, the solvent was removed under reduced pressure and the residue partitioned between water (80ml) and ethyl acetate (100ml). The aqueous layer was further extracted with ethyl acetate (2x80ml) and the combined organic layers
15 washed with brine (100ml), dried (MgSO₄) and concentrated under reduced pressure. The crude product was recrystallised from isopropyl ether-heptane to give the title compound as white needles (320mg) m.p. 177-179°. δ H (CDCl₃) 7.70 (1H, m), 7.51 (1H, d, $\underline{\text{J}}$ 8.0Hz), 7.38 (1H, d, $\underline{\text{J}}$ 8.0Hz), 7.40 (1H, m), 7.09 (1H, d, $\underline{\text{J}}$ 7.9 Hz), 5.74 (2H, br s), 5.35 (2H, br s)
20 and 2.42 (9H, s).

The 2-cyano-3-methylthio-3-(4-tolyl)acrylamide starting material was prepared according to the method of Tominaga *et al*/ J. Het. Chem. (1990) 27, 647-660 to give the compound as white crystals m.p. 200-210°. δ H (CDCl₃) 7.31 (2H, d, $\underline{\text{J}}$ 8.4Hz), 7.10 (2H, dt, $\underline{\text{J}}$ 8.4, 1.8Hz), 6.12 (1H, br s),
25 5.54 (1H, br s), 2.41 (3H, s) and 1.90 (3H, s).

EXAMPLE 13

5-Amino-1-(4-bromophenyl)-3-(4-tolyl)pyrazole-4-carboxamide

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (928mg, 4.0mmol), 4-bromophenylhydrazine hydrochloride (894mg, 4.0mmol) and sodium hydroxide (176mg, 4.4mmol) following the procedure used for the compound of Example 12. The crude product was subjected to column chromatography (SiO₂, 10% methanol in CH₂Cl₂) and recrystallisation from ethyl acetate to give the title compound
30 as white crystals (470mg) m.p. 222-223°. δ H (CDCl₃) 7.63 (2H, dt, $\underline{\text{J}}$ 8.8,

2.2Hz), 7.52 (2H, dt, \downarrow 8.5, 2.6Hz), 7.48 (2H, d, \downarrow 7.4Hz), 7.28 (2H, d, \downarrow 8.3Hz), 5.74 (2H, br s), 5.29 (2H, br s), 2.41 (3H, s).

EXAMPLE 14

5 **5-Amino-1-[(ethoxycarbonyl)methyl]-3-(4-tolyl)pyrazole-4-carboxamide**

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (425mg, 1.83mmol), ethyl hydrazinoacetate hydrochloride (311mg, 2.01mmol) and sodium hydroxide (80mg, 2.01mmol) following the
10 procedure used for the compound of Example 12. The crude product was subjected to column chromatography (SiO₂, 10% methanol in CH₂Cl₂) and was recrystallised from ethyl acetate to give the title compound as white crystals (152mg) m.p. 179°. δ H (CDCl₃) 7.43 (2H, d, \downarrow 8.1Hz), 7.26 (2H, d, \downarrow 8.1Hz), 5.56 (2H, br s), 5.22 (2H, br s), 4.77 (2H, s), 4.27 (2H, q, \downarrow
15 7.2Hz), 2.40 (3H, s) and 1.32 (3H, t, \downarrow 7.2Hz).

EXAMPLE 15

5-Amino-1-(2-pyridyl)-3-(4-tolyl)pyrazole-4-carboxamide

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (4.64mg, 2.0mmol) and 2-hydrazinopyridine (218mg, 2.0mmol) following the procedure used for the compound of Example 12.
The title compound was obtained as a white crystalline solid (350mg) m.p. 244-247°. δ H (d⁶DMSO) 8.46 (1H, dm, \downarrow 5.0Hz), 7.97 (1H, ddd, \downarrow 8.4, 7.4, 1.9Hz), 7.85 (1H, d, \downarrow 8.4Hz), 7.68 (2H, br s), 7.47 (2H, d, \downarrow 8.1Hz), 7.31
25 (2H, d, \downarrow 7.6Hz), 7.29 (1H, signal obscured by overlapping d), 3.30 (2H, s) and 2.37 (3H, s). MS (ES⁺) 294 (MH⁺, 100%).

EXAMPLE 16

5-Amino-1-(1-naphthyl)-3-(4-tolyl)pyrazole-4-carboxamide

30 The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (464mg, 2.0mmol), 1-naphthyl hydrazine hydrochloride (389mg, 2.0mmol) and sodium hydroxide (88mg, 2.2mmol) following the procedure used for the compound of Example 12. The crude product was subjected to column chromatography (SiO₂, 50-60% ethyl acetate in
35 hexane) and was recrystallised from diethylether to give the title compound as pink crystals (185mg) m.p. 195°. δ H (CDCl₃) 8.00 (1H, d, \downarrow

8.3Hz), 7.95 (1H., m), 7.73-7.55 (7H, m), 7.30 (2H, d, Δ 8.3Hz), 5.52 (2H, br s), 5.16 (2H, br s) and 2.42 (3H, s).

EXAMPLE 17

5-Amino-1-(2-tolyl)-3-(4-tolyl)pyrazole-4-carboxamide

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (464mg, 2.0mmol), 2-tolylhydrazine hydrochloride (350mg, 2.2mmol) and sodium hydroxide (88mg, 2.2mmol) following the procedure used for the compound of Example 12. The crude product was subjected to column chromatography (SiO₂, 75% ethyl acetate in hexane) to give the title compound as a yellow solid (30mg) m.p. 133-135°. δ H (CDCl₃) 7.52 (2H, d, Δ 8.1Hz), 7.38 (4H, m), 7.28 (2H, d, Δ 7.4Hz), 5.40 (4H, m), 2.40 (3H, s) and 2.23 (3H, s).

EXAMPLE 18

5-Amino-1-(4-methoxyphenyl)-3-(4-tolyl)pyrazole-4-carboxamide

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (232mg, 1.0mmol), 4-methoxyphenylhydrazine hydrochloride (192mg, 1.1mmol) and sodium hydroxide (44mg, 1.1mmol) following the procedure used for the compound of Example 12. The crude product was purified by chromatography (SiO₂, 75% ethyl acetate in hexane) and recrystallisation from ethyl acetate-hexane to give the title compound as white crystals (101mg) m.p. 174-175°. δ H (d⁶DMSO) 7.49-7.43 (4H, m), 7.28 (2H, d, Δ 7.8Hz), 7.07 (2H, d, Δ 8.9Hz), 6.32 (2H, br s), 3.81 (3H, s) and 2.29 (3H, s), one set of amino protons not observed. MS (ES⁺) 323 (MH⁺, 100%).

EXAMPLE 19

5-Amino-1-(4-nitrophenyl)-3-(4-tolyl)pyrazole-4-carboxamide

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acetamide (464mg, 2.0mmol) and 4-nitrophenylhydrazine (337mg, 2.2mmol) following the procedure used for the compound of Example 12. The crude product was purified by column chromatography (SiO₂, 2% acetic acid, 5% methanol in CH₂Cl₂) to give the title compound as a yellow solid (14mg) m.p. 299-300°. δ H (d⁶DMSO) 8.42 (2H, d, Δ 8.6Hz), 8.21 (2H, d, Δ 8.7 Hz), 7.80 (2H, d, Δ 8.0Hz) and 7.75 (2H, d, Δ 7.9Hz).

EXAMPLE 20**5-Amino-1-(3-nitrophenyl)-3-(4-tolyl)pyrazole-4-carboxamide**

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (464mg, 2.0mmol), 3-nitrophenylhydrazine hydrochloride (417mg, 2.2mmol) and sodium hydroxide (88mg, 2.2mmol) following the procedure used for the compound of Example 12. The crude product was purified by column chromatography (SiO₂, 50% ethyl acetate in hexane) and recrystallisation from ethyl acetate to give the title compound as white crystals (50mg) m.p. 237-238°. δ H (d⁶DMSO) 8.42 (1H, s), 8.21 (1H, d, \downarrow 7.8Hz), 8.11 (1H, d, \downarrow 7.8Hz), 7.79 (1H, t, \downarrow 8.2Hz), 7.50 (2H, d, \downarrow 8.0Hz), 7.30 (2H, d, \downarrow 8.1Hz), 6.70 (2H, s), 5.50 (2H, br s) and 2.37 (3H, s).

EXAMPLE 21**5-Amino-1-(3-aminophenyl)-3-(4-tolyl)pyrazole-4-carboxamide**

10% Palladium on carbon (100mg) was added to a de-gassed solution of the compound of Example 20 (120mg, 0.36mmol) and ammonium formate (30mg, 4.8mmol) in methanol. The reaction was stirred at room temperature and under nitrogen for 18h. The reaction mixture was filtered through a pad of Celite® and ethanol removed under reduced pressure. The residue was purified by column chromatography (SiO₂, ethyl acetate) to give the title compound (13mg) as yellow crystals after trituration with diethyl ether m.p. 220-222°. δ H (CDCl₃) 7.45 (2H, d, \downarrow 8.0Hz), 7.30-7.20 (3H, m), 6.90 (1H, d, \downarrow 7.9Hz), 6.81 (1H, s), 6.62 (1H, d, \downarrow 8.0Hz), 5.41 (2H, br s), 2.63 (2H br s) and 2.39 (3H, s). MS (ES⁺) 308 (MH⁺, 100%).

EXAMPLE 22**5-Amino-1-(3-hydroxypropyl)-3-(4-tolyl)pyrazole-4-carboxamide**

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (464mg, 2.0mmol), sodium carbonate (424mg, 4.0mmol) and 1-(3-hydroxypropyl)hydrazinium trifluoroacetate (449mg, 2.2mmol) following the procedure used for the compound of Example 12. The crude product was subjected to column chromatography (SiO₂, 8% methanol in CH₂Cl₂) and was recrystallised from ethyl acetate to give the title compound as white crystals (240mg) m.p. 164-165°. δ H (CDCl₃) 7.43 (2H, d, \downarrow 8.1Hz), 7.26 (2H, d, \downarrow 7.8Hz), 5.73 (2H, br s), 5.18 (2H, br s),

4.12 (2H, t, \downarrow 6.1Hz), 3.66 (2H, t, \downarrow 5.5Hz), 2.40 (3H, s), 2.04 (2H, quintet, \downarrow 6.1Hz) and 1.59 (1H, br s).

The hydrazine starting material was prepared following the method of A. Collet *et al* J. Org. Chem. 1993, 58, 4791-4793. A solution of N-(tert-butoxycarbonyl)-3-(4-cyanophenyl)-oxaziridine (1.03g, 4.2mmol) in anhydrous diethyl ether (10ml) was added to a solution of 3-amino-1-propanol (300mg, 4.0mmol) in diethyl ether (10ml) and the mixture stirred at room temperature for 2h. Solvent was removed under reduced pressure and the residue purified by chromatography (SiO₂, 3-5% methanol in CH₂Cl₂) to give 3-[1-(tert-butoxycarbonyl)hydrazino]-1-propanol as a white solid (400mg). δ H (CDCl₃) 6.14 (1H, br s), 3.78 (2H, t, \downarrow 5.6Hz), 3.04 (2H, t, \downarrow 6.1Hz), 1.71 (2H, quintet, \downarrow 6.0Hz) and 1.46 (9H, s). MS (ES⁺) 191 (MH⁺, 100%). Treatment of this compound with trifluoroacetic acid gave the required 1-(3-hydroxypropyl)hydrazinium trifluoroacetate which was used without further purification.

EXAMPLE 23

5-Amino-1-[2-(1-hydroxy-2-methyl)propyl]-3-(4-tolyl)pyrazole-4-carboxamide

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (418mg, 1.8mmol), sodium carbonate (424mg, 4.0mmol) and 1-[2-(1-hydroxy-2-methyl)propyl]hydrazinium trifluoroacetate (412mg, 2.0mmol) following the procedure used for the compound of Example 12. The crude product was subjected to column chromatography (SiO₂, 4% methanol in CH₂Cl₂) to give the title compound as a white solid (150mg) m.p. 219-220°. δ H (CDCl₃) 7.43 (2H, d, \downarrow 7.8Hz), 7.26 (2H, d, \downarrow 7.8Hz), 5.78 (2H, br s), 5.22 (2H, br s), 4.22 (1H, t, \downarrow 7.1Hz), 3.88 (2H, d, \downarrow 6.6Hz), 2.40 (3H, s), and 1.58 (6H, s). MS (ES⁺) 289 (MH⁺, 100%).

The hydrazine starting material used in the above procedure was obtained from 2-amino-2-methyl-1-propanol (383mg, 4.3mmol) in a similar manner to the hydrazine prepared in Example 22. This gave 2-[2-(tert-butoxycarbonyl)hydrazino]-2-methyl-1-propanol as a clear gum (400mg). δ H (CDCl₃) 6.39 (1H, br s), 3.19 (2H, s), 1.42 (9H, s) and 0.97 (6H, s).

Treatment of this compound with trifluoroacetic acid gave the required 1-[2-(1-hydroxy-2-methyl)propyl]hydrazinium trifluoroacetate which was used without further purification.

EXAMPLE 24**5-Amino-1-(3-carboxyphenyl)-3-(4-tolyl)pyrazole-4-carboxamide**

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (464mg, 2.0mmol), 3-carboxyphenylhydrazine (304mg, 2.0mmol) and triethylamine (2ml) following the procedure used for the compound of Example 12. The crude product was subjected to column chromatography (SiO₂, 2% acetic acid, 5% methanol in CH₂Cl₂) to give the title compound as a light yellow solid (340mg) m.p. 232-235°. δ H (d⁶DMSO) 8.14 (1H, s), 7.93 (1H, d, \downarrow 7.9Hz), 7.86 (1H, d, \downarrow 9.0Hz), 7.64 (1H, t, \downarrow 7.8Hz), 7.47 (2H, d, \downarrow 8.1Hz), 7.30 (2H, d, \downarrow 8.1Hz), 6.55 (1H, br s), 6.53 (1H, br s) and 2.36 (3H, s), carboxyl proton and amino protons not observed. MS (ES, +27V) 337 (MH⁺, 100%);

EXAMPLE 25**5-Amino-1-(4-carboxyphenyl)-3-(4-tolyl)pyrazole-4-carboxamide**

The title compound was prepared from 2-cyano-3-methylthio-3-(4-tolyl)acrylamide (464mg, 2.0mmol) and 4-hydrazinobenzoic acid (334mg, 2.2mmol) following the procedure used for the compound of Example 12. The crude product was purified by column chromatography (SiO₂, 5-10% methanol +2% acetic acid in CH₂Cl₂) and by trituration with methanol to give the title compound as a light yellow solid (497mg) m.p. >310° dec. δ H (d⁶DMSO) 8.06 (2H, d, \downarrow 8.7Hz), 7.75 (2H, d, \downarrow 8.6Hz), 7.48 (2H, d, \downarrow 8.1Hz), 7.29 (2H, d, \downarrow 8.0Hz), 6.63 (2H, br s) and 2.36 (3H, s), carboxyl proton and amino protons not observed.

EXAMPLE 26**5-Amino-1-{3-[N-(N'-tert-butoxycarbonyl)-2-aminoethyl]benzamido}-3-(4-tolyl)pyrazole-4-carboxamide**

To a solution of the compound of Example 24 (150mg, 0.45mmol), N-hydroxysuccinimide (59mg, 0.51mmol), N-methylmorpholine (0.5ml, 4.50mmol) and N-(tert-butoxycarbonyl)ethylenediamine (82mg, 0.51mmol) in anhydrous DMF (15ml) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (96mg, 0.51mmol) and the mixture stirred at room temperature for 20h. The reaction was partitioned between ethyl acetate (50ml) and water (50ml). The layers were separated and the

aqueous extracted with further portions of ethyl acetate (25ml x 2). The combined ethyl acetate extracts were washed with brine (50ml), dried (MgSO₄) and concentrated under reduced pressure to give a yellow solid. The crude product was subjected to column chromatography (SiO₂, 4-5% methanol in CH₂Cl₂) to give the title compound as a white solid (100mg).
5 δ H (d⁶DMSO) 8.57 (1H, t, \downarrow 6.9Hz), 8.03 (1H, s), 7.83 (1H, d, \downarrow 7.7Hz), 7.74 (1H, d, \downarrow 8.9Hz), 7.61 (1H, t, \downarrow 7.9Hz), 7.45 (2H, d, \downarrow 8.1Hz), 7.30 (2H, d, \downarrow 8.1Hz), 6.88 (1H, t, \downarrow 6.9Hz), 6.55 (2H, br s), 3.38 (2H, m), 3.10 (2H, q, \downarrow 6.0Hz), 2.36 (3H, s) and 1.35 (9H, s). MS (ES⁺) 479 (MH⁺,
10 100%).

EXAMPLE 27

5-Amino-1-[3-(N-{2-aminoethyl}benzamido)]-3-(4-tolyl)pyrazole-4-carboxamide trifluoroacetate

15 Trifluoroacetic acid (10ml) was added to a suspension of the compound of Example 26 (100mg, 0.21mmol) in CH₂Cl₂ (10ml). After 20 minutes the reaction mixture was concentrated under reduced pressure and the product triturated with diethyl ether to give the title compound as a buff powder (75mg). δ H (d⁶DMSO) 8.70 (1H, t, \downarrow 3.7Hz), 8.06 (1H, s), 7.87
20 (1H, d, \downarrow 7.3Hz), 7.78 (3H, m), 7.64 (1H, t, \downarrow 7.3Hz), 7.45 (2H, d, \downarrow 8.0Hz), 7.30 (2H, d, \downarrow 8.0Hz), 6.55 (2H, br s), 3.53 (2H, q, \downarrow 7.0Hz), 3.01 (2H, m) and 2.39 (3H, s). MS (ES⁺) 379 (MH⁺, 100%), 362 (MH⁺ -NH₃, 45%).

EXAMPLE 28

5-Amino-1-[3-[N-(N'-(tert-butoxycarbonyl)-3-aminopropyl)]benzamido]-3-(4-tolyl)pyrazole-4-carboxamide

The title compound was prepared from the compound of Example 24 (215mg, 0.64mmol) and N-(tert-butoxycarbonyl)-1,3-diaminopropane (134mg, 0.77mmol) following the procedure used for the compound of
30 Example 26. The crude product was purified by column chromatography (SiO₂, 5% methanol in CH₂Cl₂) to give the title compound as a white solid (80mg) m.p. 111-113°. δ H (d⁶DMSO) 8.55 (1H, t, \downarrow 6.2Hz), 8.03 (1H, s with fine coupling), 7.83 (1H, d, \downarrow 7.9Hz), 7.75 (1H, d, \downarrow 8.9Hz), 7.61 (1H, t, \downarrow 7.9Hz), 7.46 (2H, d, \downarrow 8.1Hz), 7.30 (2H, d, \downarrow 8.1Hz), 6.78 (1H, t, \downarrow
35 6.2Hz), 6.55 (2H, br s), 3.25 (2H, q, \downarrow 6.6Hz), 2.96 (2H, q, \downarrow 6.3Hz), 2.36 (3H, s), 1.63 (2H, quintet, \downarrow 6.9Hz), and 1.36 (9H, s).

EXAMPLE 29**5-Amino-1-[3-(N-(3-aminopropyl)benzamido)]-3-(4-tolyl)pyrazole-4-carboxamide trifluoroacetate**

- 5 The title compound was prepared by treating the compound of Example 28 (80mg, 0.17mmol) with trifluoroacetic acid following the procedure used for the compound of Example 27. This gave the title compound as a white solid (86mg). δ H (CDCl₃) 8.74 (1H, t, \downarrow 5.9Hz), 8.04 (1H, s), 7.85 (1H, d, \downarrow 7.8Hz), 7.79 (3H, m), 7.62 (1H, t, \downarrow 7.9Hz), 7.45 (2H, d, \downarrow 8.0Hz), 7.30
10 (2H, d, \downarrow 7.9Hz), 6.56 (2H, br s), 3.56 (2H, br s), 3.34 (2H, q, \downarrow 5.9Hz), 2.84 (2H, br s), 2.36 (3H, s) and 1.80 (2H, quintet, \downarrow 7.0Hz). MS (ES⁺) 393 (MH⁺, 100%).

EXAMPLE 30

15 **5-Amino-1-[4-[N-(N'-(tert-butoxycarbonyl)-3-aminopropyl)]benz-amido]-3-(4-tolyl)pyrazole-4-carboxamide**

- The title compound was prepared from the compound of Example 25 (160mg, 0.49mmol) and N-(tert-butoxycarbonyl)-1,3-diaminopropane (101mg, 0.58mmol) following the procedure used for the compound of
20 Example 26. The crude product was purified by column chromatography (SiO₂, 5% methanol in CH₂Cl₂) to give the title compound as an orange solid (135mg) m.p. 109-110°. δ H (d⁶DMSO) 8.51 (1H, t, \downarrow 3.8Hz), 7.97 (2H, d, \downarrow 8.5Hz), 7.71 (2H, d, \downarrow 8.6Hz), 7.43 (2H, d, \downarrow 8.0Hz), 7.30 (2H, d, \downarrow 8.3Hz), 6.84 (1H, t, \downarrow 2.0Hz), 6.59 (2H, s), 3.28 (2H, m), 2.97 (2H, m),
25 2.36 (3H, s), 1.65 (1H, m) and 1.36 (9H, s). MS (ES⁺) 493 (MH⁺, 100%).

EXAMPLE 31**5-Amino-1-[4-(N-(3-aminopropyl))benzamido]-3-(4-tolyl)pyrazole-4-carboxamide trifluoroacetate**

- 30 The title compound was prepared by treating the compound of Example 30 (110mg, 0.22mmol) with trifluoroacetic acid following the procedure used for the compound of Example 27. This gave the title compound as pale pink crystals (30mg) m.p. 118-120°. δ H (d⁶DMSO) 8.70 (1H, t, \downarrow 3.5Hz), 8.00 (2H, d, \downarrow 8.6Hz), 7.75 (2H, d, \downarrow 8.5Hz), 7.45 (2H, d, \downarrow 7.9Hz),
35 7.30 (2H, d, \downarrow 7.7Hz), 6.59 (1H, m), 3.35 (2H, m), 2.84 (2H, m), 2.36 (3H, s) and 1.81 (2H, m). MS (ES⁺) 393 (MH⁺, 100%).

BIOLOGICAL ACTIVITY

5 The following assays were used to demonstrate the activity and selectivity of compounds according to the invention. Enzymes for the assays were either obtained commercially or purified from known natural or recombinant sources using conventional methods.

p56^{lck} kinase assay

10 The tyrosine kinase activity of p56^{lck} was determined using a RR-src peptide (RRLIEDNEYTARG) and [γ -³³P]ATP as substrates. Quantitation of the ³³P-phosphorylated peptide formed by the action of p56^{lck} was achieved using an adaption of the method of Geissler *et al* (J. Biol. Chem. (1990) 265, 22255-22261).

15 All assays were performed in 20mM HEPES pH 7.5 containing 10mM MgCl₂, 10mM MnCl₂, 0.05% Brij, 1 μ M ATP (0.5 μ Ci [γ -³³P]ATP) and 0.8mg/ml RR-src. Inhibitors in dimethylsulphoxide (DMSO) were added such that the final concentration of DMSO did not exceed 1%, and enzyme
20 such that the consumption of ATP was less than 10%. After incubation at 30°C for 15min, the reaction was terminated by the addition of one-third volume of stop reagent (0.25mM EDTA and 33mM ATP in dH₂O). A 15 μ l aliquot was removed, spotted onto a P-30 filtermat (Wallac, Milton Keynes, UK), and washed sequentially with 1% acetic acid and dH₂O to remove
25 ATP. The bound ³³P-RR-src was quantitated by scintillation counting of the filtermat in a Betaplate scintillation counter (Wallac, Milton Keynes, UK) after addition of Meltilex scintillant (Wallac, Milton Keynes, UK).

30 The dpm obtained, being directly proportional to the amount of ³³P-RR-src produced by p56^{lck}, were used to determine the IC₅₀ for each compound. The IC₅₀ was defined as the concentration of compound required to reduce the production of ³³P-RR-src by 50%.

35 In this test, compounds according to the invention, such as the compounds of the Examples, have IC₅₀ values of around 5 μ M and below.

Zap-70 and Csk kinase assays

Inhibitor activity against Zap-70 or Csk kinase was determined using a capture assay based on that employed above for p56^{lck} but with the following modifications. The RR-src peptide was replaced with polyGlu-Tyr (Sigma; Poole, UK) at a final concentration of 17 µg/ml. After addition of the stopped reaction to the filtermat, trichloroacetic acid 10% (w/v) was employed as the wash reagent instead of acetic acid and a final wash in absolute ethanol was also performed before scintillation counting. In these assays, compounds of the invention, such as the compounds of the Examples had little or no measurable activity against either Zap-70 or Csk kinases.


Protein kinase C assay

Inhibitor activity against protein kinase C (PKC) was determined using PKC obtained from Sigma Chemical Company (Poole, UK) and a commercially available assay system (Amersham International plc, Amersham, UK). Briefly, PKC catalyses the transfer of the γ-phosphate (³²p) of ATP to the threonine group on a peptide specific for PKC. Phosphorylated peptide is bound to phosphocellulose paper and subsequently quantified by scintillation counting. The inhibitor potency is expressed as either (i) the concentration required to inhibit 50% of the enzyme activity (IC₅₀) or (ii) the percentage inhibition achieved by 10µM inhibitor. In this assay, compounds of the invention, such as the compounds of the Examples had little or no measurable activity at concentrations at which they inhibit the activity of p56^{lck}.

CLAIMS

1. A compound of formula (1):

5



wherein

Ar is an optionally substituted aromatic or heteroaromatic group;

10 X¹ is an oxygen or sulphur atom;

R¹ is a hydrogen atom or a methyl group;


R² is a hydrogen atom or a group -Alk¹ or -X²Alk¹ where Alk¹ is an optionally substituted aliphatic or heteroaliphatic group and X² is a -C(O)-, -C(S)-, or -S(O)_n group where n is an integer 1 or 2;

15 R³ is a hydrogen atom or a group -Alk², [where Alk² is as defined for Alk¹], -X²Alk², -Ar¹ [where Ar¹ is an optionally substituted aromatic or heteroaromatic group], -Alk²Ar¹, or -X²Alk²Ar¹;
and the salts, solvates, hydrates and N-oxides thereof.

- 20 2. A compound according to Claim 1 wherein X¹ is an oxygen atom.
3. A compound according to Claim 1 or Claim 2 wherein R¹ and R² is each a hydrogen atom.
- 25 4. A compound according to any one of Claim 1 to Claim 3 wherein Ar is an optionally substituted phenyl group.
5. A compound according to any one of Claim 1 to Claim 4 wherein R³ is an Alk², -X³Alk², -Ar¹, -Alk²Ar or -X³Alk²Ar¹ group.

30

6. A compound according to Claim 5 wherein R^3 is an $-Alk^2$ or $-Ar^1$ group.
7. A compound according to Claim 6 wherein R^3 is an optionally substituted C_{1-6} alkyl, an optionally substituted phenyl or an optionally substituted pyridyl group.
8. A pharmaceutical composition comprising a compound of formula (1):



(1)

wherein

Ar is an optionally substituted aromatic or heteroaromatic group;

X^1 is an oxygen or sulphur atom;

R^1 is a hydrogen atom or a methyl group;

R^2 is a hydrogen atom or a group $-Alk^1$ or $-X^2Alk^1$ where Alk^1 is an optionally substituted aliphatic or heteroaliphatic group and X^2 is a $-C(O)-$, $-C(S)-$, or $-S(O)_n$ group where n is an integer 1 or 2;

R^3 is a hydrogen atom or a group $-Alk^2$, [where Alk^2 is as defined for Alk^1], $-X^2Alk^2$, $-Ar^1$ [where Ar^1 is an optionally substituted aromatic or heteroaromatic group], $-Alk^2Ar^1$, or $-X^2Alk^2Ar^1$;

and the salts, solvates, hydrates and N-oxides thereof.

together with one or more pharmaceutically acceptable carriers, excipients or diluents.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/01120

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D231/38 A61K31/415 C07D401/04 C07D405/04 C07D409/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 285 932 A (CIBA-GEIGY AG) 16 August 1972 see page 6 - page 7; claims 1,18 ---	1-3,5-8
X	US 3 947 467 A (VERGE JOHN POMFRET ET AL) 30 March 1976 see column 11; example 2 ---	1-3,5-8
A	JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 4, 19 February 1993, WASHINGTON US, pages 425-432, XP000569376 T.R. BURKE JR. ET AL.: "Bicyclic Compounds as Ring-Constrained Inhibitors of Protein-Tyrosine Kinase p56lck1" see the whole document --- -/--	1-8



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 August 1997

Date of mailing of the international search report

22.08.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (- 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (- 31-70) 340-3016

Authorized officer

Fink, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/01120

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 96 14843 A (COR THERAPEUTICS INC) 23 May 1996 see the whole document -----	1-8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/01120

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1285932 A	16-08-72	AT 303021 A	15-10-72
		BE 751453 A	04-12-70
		BG 17314 A	25-07-73
		CA 925873 A	08-05-73
		CH 549595 A	31-05-74
		DE 2027593 A	10-12-70
		FR 2052934 A	16-04-71
		NL 7007848 A	08-12-70
		SE 366318 B	22-04-74
		ZA 7003794 A	27-01-71

US 3947467 A	30-03-76	GB 1478364 A	29-06-77
		US 3980794 A	14-09-76
		AR 203854 A	31-10-75
		AR 205814 A	07-06-76
		AR 204130 A	20-11-75
		AT 337691 B	11-07-77
		AU 7052874 A	08-01-76
		BE 818417 A	03-02-75
		DE 2431775 A	20-02-75
		FR 2240009 A	07-03-75
		JP 50047978 A	28-04-75
		NL 7410033 A	04-02-75
		SE 7409957 A	03-02-75
		ZA 7403887 A	25-06-75

WO 9614843 A	23-05-96	AU 4156196 A	06-06-96
